TOVX Stock Catalyst: Theriva Biologics Announces Pricing Of $7.5M Public Offering And Reports VIRAGE Phase 2b Trial Findings

Theriva Biologics, Inc. (TOVX) announced the pricing of a public offering of up to 6,818,180 shares of common stock and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant. The total offering is expected to raise $7.5 million. Additionally, the company reported topline findings from the VIRAGE Phase 2b trial of VCN-01 in pancreatic cancer.

The public offering includes 6,818,180 shares of common stock and accompanying warrants, priced at $1.10 per share and warrant. The company also disclosed preliminary results from its VIRAGE Phase 2b trial, though specific outcomes were not detailed in the announcement.

As of the latest data, Theriva Biologics has a free float of 32,990,300 shares and 33,739,600 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.